Innoviva Total Long-Term Assets 2010-2024 | INVA
Innoviva total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Innoviva Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$899 |
| 2022 |
$788 |
| 2021 |
$613 |
| 2020 |
$658 |
| 2019 |
$294 |
| 2018 |
$349 |
| 2017 |
$167 |
| 2016 |
$181 |
| 2015 |
$195 |
| 2014 |
$269 |
| 2013 |
$198 |
| 2012 |
$107 |
| 2011 |
$14 |
| 2010 |
$15 |
| 2009 |
$19 |
Innoviva Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$867 |
| 2024-03-31 |
$956 |
| 2023-12-31 |
$899 |
| 2023-09-30 |
$883 |
| 2023-06-30 |
$795 |
| 2023-03-31 |
$833 |
| 2022-12-31 |
$788 |
| 2022-09-30 |
$873 |
| 2022-06-30 |
$737 |
| 2022-03-31 |
$790 |
| 2021-12-31 |
$613 |
| 2021-09-30 |
$650 |
| 2021-06-30 |
$641 |
| 2021-03-31 |
$715 |
| 2020-12-31 |
$658 |
| 2020-09-30 |
$350 |
| 2020-06-30 |
$379 |
| 2020-03-31 |
$321 |
| 2019-12-31 |
$294 |
| 2019-09-30 |
$309 |
| 2019-06-30 |
$325 |
| 2019-03-31 |
$339 |
| 2018-12-31 |
$349 |
| 2018-09-30 |
$157 |
| 2018-06-30 |
$160 |
| 2018-03-31 |
$164 |
| 2017-12-31 |
$167 |
| 2017-09-30 |
$170 |
| 2017-06-30 |
$174 |
| 2017-03-31 |
$177 |
| 2016-12-31 |
$181 |
| 2016-09-30 |
$184 |
| 2016-06-30 |
$188 |
| 2016-03-31 |
$191 |
| 2015-12-31 |
$195 |
| 2015-09-30 |
$214 |
| 2015-06-30 |
$218 |
| 2015-03-31 |
$226 |
| 2014-12-31 |
$269 |
| 2014-09-30 |
$280 |
| 2014-06-30 |
$252 |
| 2014-03-31 |
$216 |
| 2013-12-31 |
$198 |
| 2013-09-30 |
$144 |
| 2013-06-30 |
$137 |
| 2013-03-31 |
$117 |
| 2012-12-31 |
$107 |
| 2012-09-30 |
$101 |
| 2012-06-30 |
$96 |
| 2012-03-31 |
$13 |
| 2011-12-31 |
$14 |
| 2011-09-30 |
$14 |
| 2011-06-30 |
$14 |
| 2011-03-31 |
$15 |
| 2010-12-31 |
$15 |
| 2010-09-30 |
$15 |
| 2010-06-30 |
$16 |
| 2010-03-31 |
$18 |
| 2009-12-31 |
$19 |
| 2009-09-30 |
$21 |
| 2009-06-30 |
$22 |
| 2009-03-31 |
$25 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
